Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

TRISENOX

M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Developer of arsenic trioxide injection. The company's product is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 41 Moores Road
  • Malvern, PA 19355
  • United States

+1 (610) 000-0000

TRISENOX Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore TRISENOX‘s full profile, request access.

Request full access to PitchBook

TRISENOX Executive Team (1)

Name Title Board
Seat
Contact
Info
Danielle Leap Senior Product Manager